The new StrataDx Onychodystrophy PCR test with terbinafine resistance enables you to understand the likelihood of treatment effectiveness in days, instead of months.
Eliminate terbinafine “watchful waiting” period
Avoid unnecessary medications & potential side effects
Increase treatment efficacy & patient satisfaction
Causative infectious organisms are colorless and invisible to the eye
Laboratory testing provides objective information for precise treatment
While superficial onychomycosis caused by Trichophyton rubrum and T. mentagrophytes can often be treated with terbinafine, an increasing rate of cases with antifungal resistance mutations is impeding treatment success.
There is a serious global public health concern that antifungal treatment, traditionally oral and/or topical terbinafine, may be ineffective against 12 resistant mutation strains found in members of the Trichophyton genera.
StrataDx’s highly experienced molecular analysis team developed an advanced real-time PCR terbinafine resistance reflex to seamlessly integrate with our Onychodystrophy PCR test to accurately detect when 12 terbinafine resistant mutations are present in T. rubrum and T. mentagrophytes.
- At initial presentation of nail dystrophy
- When considering terbinafine therapy
- Cases of treatment failure
Just as the current onychodystrophy test provides cost effectiveness through a proprietary reflex algorithm, this new addition will only reflex to terbinafine resistance when it identifies T. rubrum and/or T. mentagrophytes. Furthermore, our test is able to detect 12 current mutations in just four reactions. StrataDx is contracted with most insurance plans throughout the United States, providing clients and their patients with a superior level of access to testing services.
Terbinafine treatment failure may occur in patients with terbinafine resistant strains of dermatophytic fungi. Many times, despite having a positive T. rubrum or T. mentagrophytes diagnosis, patients do not improve. In these cases, where there is a poor response or non-responsiveness to the recommended antifungal, patients may grow frustrated, lose valuable time with unnecessary treatment and incur added Rx costs. In addition, there are secondary bacterial infections, which are potentially the most significant complication leading to adverse outcomes.
StrataDx’s PCR Testing Advantages
- Reflexes to secondary testing only when positive to reduce medical costs
- Detects 12 terbinafine resistance mutations in just 4 reactions for cost effectiveness
- Identifies multiple causative organism targets in a single specimen
- Detects low levels of concentration of the causative organism
Filters out contaminants present in the collected specimen